Tasly Pharmaceutical Group Co., Ltd

XSSC:600535 Stock Report

Market Cap: CN¥21.6b

Tasly Pharmaceutical Group Valuation

Is 600535 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600535 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600535 (CN¥14.47) is trading below our estimate of fair value (CN¥51.95)

Significantly Below Fair Value: 600535 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600535?

Key metric: As 600535 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600535. This is calculated by dividing 600535's market cap by their current earnings.
What is 600535's PE Ratio?
PE Ratio24.5x
EarningsCN¥881.05m
Market CapCN¥21.62b

Price to Earnings Ratio vs Peers

How does 600535's PE Ratio compare to its peers?

The above table shows the PE ratio for 600535 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.4x
600062 China Resources Double-Crane PharmaceuticalLtd
15.8x16.6%CN¥21.4b
600329 Tianjin Pharmaceutical Da Ren Tang Group
26.5x20.8%CN¥21.5b
600380 Joincare Pharmaceutical Group IndustryLtd
14.2x11.8%CN¥20.9b
300558 Betta Pharmaceuticals
44.9x26.7%CN¥20.7b
600535 Tasly Pharmaceutical Group
24.5x22.7%CN¥21.6b

Price-To-Earnings vs Peers: 600535 is good value based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (25.4x).

Price to Earnings Ratio vs Industry

How does 600535's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600535 24.5xIndustry Avg. 29.6xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600535 is good value based on its Price-To-Earnings Ratio (24.5x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 600535's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600535 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.5x
Fair PE Ratio29.7x

Price-To-Earnings vs Fair Ratio: 600535 is good value based on its Price-To-Earnings Ratio (24.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600535 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥14.47
CN¥17.36
+19.9%
8.8%CN¥19.56CN¥15.30n/a5
Nov ’25CN¥14.90
CN¥17.36
+16.5%
8.8%CN¥19.56CN¥15.30n/a5
Oct ’25CN¥16.15
CN¥17.23
+6.7%
8.7%CN¥19.56CN¥15.30n/a5
Sep ’25CN¥14.23
CN¥17.23
+21.1%
8.7%CN¥19.56CN¥15.30n/a5
Aug ’25CN¥14.08
CN¥16.97
+20.5%
11.1%CN¥19.56CN¥14.00n/a5
Jul ’25CN¥12.89
CN¥16.17
+25.5%
20.4%CN¥19.56CN¥10.00n/a5
Jun ’25CN¥13.93
CN¥14.87
+6.8%
28.6%CN¥19.56CN¥9.50n/a5
May ’25CN¥15.46
CN¥13.97
-9.7%
32.5%CN¥19.56CN¥9.50n/a4
Apr ’25CN¥16.33
CN¥14.92
-8.6%
40.7%CN¥22.48CN¥8.00n/a4
Mar ’25CN¥16.81
CN¥14.92
-11.2%
40.7%CN¥22.48CN¥8.00n/a4
Feb ’25CN¥14.69
CN¥14.92
+1.6%
40.7%CN¥22.48CN¥8.00n/a4
Jan ’25CN¥17.02
CN¥14.62
-14.1%
37.7%CN¥20.86CN¥8.00n/a4
Dec ’24CN¥15.29
CN¥13.90
-9.1%
37.6%CN¥19.20CN¥8.00n/a4
Nov ’24CN¥14.92
CN¥13.78
-7.7%
39.0%CN¥19.20CN¥7.50CN¥14.904
Oct ’24CN¥14.52
CN¥12.76
-12.2%
36.2%CN¥19.20CN¥7.50CN¥16.154
Sep ’24CN¥13.99
CN¥11.58
-17.2%
27.3%CN¥14.92CN¥7.50CN¥14.234
Aug ’24CN¥13.92
CN¥12.28
-11.8%
33.7%CN¥17.90CN¥7.30CN¥14.084
Jul ’24CN¥14.51
CN¥12.20
-15.9%
34.4%CN¥17.90CN¥7.30CN¥12.894
Jun ’24CN¥15.54
CN¥12.10
-22.1%
35.3%CN¥17.90CN¥7.30CN¥13.934
May ’24CN¥15.14
CN¥12.10
-20.1%
35.3%CN¥17.90CN¥7.30CN¥15.464
Apr ’24CN¥15.05
CN¥10.82
-28.1%
34.6%CN¥16.67CN¥7.30CN¥16.334
Mar ’24CN¥14.12
CN¥10.13
-28.3%
22.8%CN¥13.20CN¥7.80CN¥16.814
Feb ’24CN¥11.60
CN¥10.13
-12.7%
22.8%CN¥13.20CN¥7.80CN¥14.694
Jan ’24CN¥10.76
CN¥10.18
-5.4%
22.2%CN¥13.20CN¥8.00CN¥17.024
Dec ’23CN¥11.66
CN¥10.18
-12.7%
22.2%CN¥13.20CN¥8.00CN¥15.294
Nov ’23CN¥11.13
CN¥10.18
-8.6%
22.2%CN¥13.20CN¥8.00CN¥14.924

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

7D

-2.6%

1Y

13.6%